tiprankstipranks
Trending News
More News >

Fosun Pharma’s Subsidiary Drug Receives Breakthrough Therapy Designation

Story Highlights
Fosun Pharma’s Subsidiary Drug Receives Breakthrough Therapy Designation

Don’t Miss TipRanks’ Half-Year Sale

Shanghai Fosun Pharmaceutical (Group) Co ( (HK:2196) ) has issued an update.

Shanghai Fosun Pharmaceutical announced that its subsidiary’s FCN-159 tablets have been granted breakthrough therapy designation by the National Medical Products Administration for treating children with Langerhans cell histiocytosis. This designation highlights the company’s commitment to developing innovative treatments and may enhance its position in the pharmaceutical industry, potentially benefiting stakeholders by accelerating the drug’s development and approval process.

More about Shanghai Fosun Pharmaceutical (Group) Co

Shanghai Fosun Pharmaceutical (Group) Co., Ltd. is a joint stock limited company incorporated in China, operating in the pharmaceutical industry. The company focuses on the development and manufacturing of innovative drugs, with a market focus on advanced solid tumors, neurofibromatosis type 1, and other related conditions.

YTD Price Performance: -2.41%

Average Trading Volume: 5,593,387

Technical Sentiment Signal: Sell

Current Market Cap: HK$61.09B

Find detailed analytics on 2196 stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1